

Sponsor:
Ben IRVING
GVS FILTER TECHNOLOGY UK LTD.
NFC House, Vickers Industrial Estate
Mellishaw Lane
Morecambe, Lancashire, LA3 3EN
UNITED KINGDOM

Bacterial Filtration Efficiency (BFE) GLP Report

Test Article: Elipse Source Control Exhalation Valve Filter

Part#: 10.022.0039.00.AA - Electrostatic Media

Lot#: 0220178

Purchase Order: FO-2121/03276/21 Study Number: 1465393-S01 Study Received Date: 04 Nov 2021 Test Started Date: 17 Nov 2021

Test Started Date: 04 Nov 2021
Test Started Date: 17 Nov 2021
Test Finished Date: 19 Nov 2021

Testing Facility: Nelson Laboratories, LLC

6280 S. Redwood Rd.

Salt Lake City, UT 84123 U.S.A.

Test Procedure(s): Standard Test Protocol (STP) Number: STP0004 Rev 19

Deviation(s): None

Summary: The BFE test is performed to determine the filtration efficiency of test articles by comparing the bacterial control counts upstream of the test article to the bacterial counts downstream. A suspension of *Staphylococcus aureus* was aerosolized using a nebulizer and delivered to the test article at a constant flow rate and fixed air pressure. The challenge delivery was maintained at $1.7 - 3.0 \times 10^3$ colony forming units (CFU) with a mean particle size (MPS) of 3.0 ± 0.3 µm. The aerosols were drawn through a six-stage, viable particle, Andersen sampler for collection. This test method complies with ASTM F2101-20 and EN 14683:2019+AC:2019, Annex B.

All test method acceptance criteria were met.

Test Side: Either

BFE Test Area: ~7.8 cm²

BFE Flow Rate: 28.3 Liters per minute (L/min)

Conditioning Parameters: 85 ± 5% relative humidity (RH) and 21 ± 5°C for a minimum of 4 hours

Positive Control Average: 2.5 x 10³ CFU

Negative Monitor Count: <1 CFU

MPS: 2.9 µm





James Luskin electronically approved

James Luskin

26 Nov 2021 18:39 (+00:00)
Study Completion Date and Time

Study Director

James Luskin

FRT0004-0001 Rev 23 Page 1 of 3



Results:

Test Article Number	Percent BFE (%)
1	>99.9
2	>99.9 ^a
3	>99.9
4	>99.9
5	>99.9

^a There were no detected colonies on any of the Andersen sampler plates for this test article.

The filtration efficiency percentages were calculated using the following equation:

$$\% BFE = \frac{C - T}{C} \times 100$$

C = Positive control average

T = Plate count total recovered downstream of the test article Note: The plate count total is available upon request

Test Article Preparation: The test articles were conditioned for a minimum of 4 hours at 21 ± 5°C and 85 ± 5% RH, prior to BFE testing.

Test Method Acceptance Criteria: The BFE positive control average shall be maintained at 1.7 - 3.0×10^3 CFU.

The MPS control average of the challenge aerosol shall be maintained at $3.0 \pm 0.3 \,\mu m$.

Procedure: A culture of S. aureus, ATCC #6538, was diluted in peptone water (PEPW) to yield challenge level counts of $1.7 - 3.0 \times 10^3$ CFU per test article. The bacterial culture suspension was pumped through a nebulizer at a controlled flow rate and fixed air pressure. The constant challenge delivery, at a fixed air pressure, formed aerosol droplets with a MPS of approximately 3.0 µm. The aerosol droplets were generated in a glass aerosol chamber and drawn through a six-stage, viable particle, Andersen sampler for collection. Test articles, positive controls, and reference material received a one minute challenge followed by a one minute vacuum cycle.

The Andersen sampler, a sieve sampler, impinged the aerosol droplets onto six soybean casein digest agar (SCDA) plates based on the size of each droplet. The agar plates were incubated at 37 ± 2°C for 48 ± 4 hours and the colonies formed by the bacteria laden aerosol droplets were then counted and converted to probable hit values using the positive hole conversion chart provided by Andersen. These converted counts were used to determine the average challenge level delivered to the test articles. The distribution ratio of the colonies on each of the six agar plates was used to calculate the MPS of the challenge aerosol.

ihs



Quality Assurance Statement

Compliance Statement: The test was conducted in accordance with the USFDA (21 CFR Parts 58, 210, 211, and 820) Regulations. This final report reflects the raw data.

Activity	Date
Study Initiation	09 Nov 2021
Phase Inspected by Quality Assurance: BFE Challenge Procedure	17 Nov 2021
Audit Results Reported to Study Director	19 Nov 2021
Audit Results Reported to Management	19 Nov 2021

Scientists	Title
Sarah Smit	Supervisor
James Luskin	Study Director

Data Disposition: The study plan, raw data and final report from this study are archived at Nelson Laboratories, LLC or an approved off-site location.

Brandon Mikesell electronically approved

Quality Assurance

23 Nov 2021 21:51 (+00:00)

Date and Time

jhs